ClearPoint Neuro (CLPT) officer settles 17,778 RSUs, 6,913 shares withheld for tax

Rhea-AI Filing Summary

ClearPoint Neuro Chief Business Officer Jeremy L. Stigall settled previously granted equity awards into common shares and had part withheld for taxes. On 2026-03-06, he exercised 17,778 restricted stock units, receiving the same number of ClearPoint Neuro common shares at an exercise price of $0.00 per share.

To cover tax obligations tied to this vesting, 6,913 common shares were delivered back to ClearPoint Neuro at $10.00 per share as a tax-withholding disposition, rather than an open-market sale. After these transactions, Stigall directly owned 87,571 common shares of ClearPoint Neuro.

Insider Trade Summary

17,778 shares exercised/converted

Mixed 3 txns

Insider STIGALL L. JEREMY

Role Chief Business Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	17,778	$0.00	--
Exercise	Common Stock	17,778	$0.00	--
Tax Withholding	Common Stock	6,913	$10.00	$69K

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Common Stock — 94,484 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STIGALL L. JEREMY

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		M		17,778	A	(1)	94,484	D
Common Stock	03/06/2026		F		6,913(2)	D	$10	87,571	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/06/2026		M			17,778	(1)	(1)	Common Stock	17,778	(1)	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

2. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

	/s/ Danilo D'Alessandro, by Power of Attorney for Jeremy L. Stigall	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ClearPoint Neuro (CLPT) report for Jeremy L. Stigall?

ClearPoint Neuro reported that Chief Business Officer Jeremy L. Stigall settled 17,778 restricted stock units into common stock. The RSUs vested and converted into 17,778 common shares, reflecting routine equity compensation rather than an open-market share purchase.

How many ClearPoint Neuro (CLPT) shares did Jeremy L. Stigall receive and retain?

Jeremy L. Stigall received 17,778 ClearPoint Neuro common shares upon RSU vesting. After 6,913 shares were delivered to the company for tax withholding, he directly held 87,571 common shares, as shown in the post-transaction holdings reported in the Form 4.

Was there any open-market buying or selling in this ClearPoint Neuro (CLPT) Form 4?

The Form 4 does not show open-market buying or selling. It records RSU vesting into 17,778 common shares and a 6,913-share disposition to ClearPoint Neuro to satisfy tax withholding, a non-market transaction made to cover tax obligations.

What does the tax-withholding transaction mean in the ClearPoint Neuro (CLPT) filing?

The filing shows 6,913 shares of ClearPoint Neuro common stock delivered to the company at $10.00 per share. According to the footnote, this represents shares withheld to satisfy tax obligations related to the vesting of restricted stock, not a discretionary market sale.

What role does Jeremy L. Stigall hold at ClearPoint Neuro (CLPT) in this Form 4?

In this Form 4, Jeremy L. Stigall is identified as an officer of ClearPoint Neuro, serving as Chief Business Officer. The reported equity transactions reflect compensation-related RSU vesting and related tax withholding tied to his executive role.